MEDICATIONS
ReliTrexed Powder for Solution for Infusion
MEDICATIONS
ReliTrexed Powder for Solution for Infusion
MEDICATIONS
ReliTrexed Powder for Solution for Infusion
ReliTrexed (Pemetrexed) Powder for Solution for Infusion (100mg/vial or 500mg/vial) is an antifolate antineoplastic agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication. It is administered as an intravenous infusion and must be administered under the supervision of a qualified physician.
Approved Indications:
- ReliTrexed® in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma or who are otherwise not candidates for curative surgery.
- ReliTrexed® in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-squamous NSCLC.
- ReliTrexed® in combination with pembrolizumab and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- ReliTrexed® is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-squamous NSCLC in patients whose disease has not progressed immediately following first-line treatment with platinum-based chemotherapy.
- ReliTrexed® is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-squamous NSCLC.